Free Trial

Nicholas Holowko Analyst Performance

Analyst at UBS Group

Nicholas Holowko is a stock analyst at UBS Group focused in the finance sector, covering 5 publicly traded companies. Over the past year, Nicholas Holowko has issued 5 stock ratings, including buy and hold recommendations. While full access to Nicholas Holowko's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Nicholas Holowko's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
5 Last 0 Years
Buy Recommendations
20.00% 1 Buy Ratings
Companies Covered
5 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy20.0%1 ratings
Hold80.0%4 ratings
Sell0.0%0 ratings

Out of 5 total stock ratings issued by Nicholas Holowko at UBS Group, the majority (80.0%) have been Hold recommendations, followed by 20.0% Buy.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NYSE
60.0% of companies on NYSE
3 companies
NASDAQ
40.0% of companies on NASDAQ
2 companies

Nicholas Holowko, an analyst at UBS Group, currently covers 5 companies listed on NYSE and NASDAQ, with the majority traded on NYSE.

Coverage Focus

Sector IconSectorPercentage
Finance
4 companies
80.0%
Medical
1 company
20.0%

Nicholas Holowko of UBS Group specializes in stock coverage within the Finance sector, with additional focus on Medical companies.

Coverage Industries

IndustryPercentage
BANKS - SOUTHEAST
2 companies
40.0%
MED - BIOMED/GENE
1 company
20.0%
BANKS - MJR REGNL
1 company
20.0%
BANKS - NORTHEAST
1 company
20.0%

Nicholas Holowko's Ratings History at UBS Group

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Synovus Financial Corp. stock logo
SNV
Synovus Financial
9/2/2025Downgrade$51.54$56.00Neutral
Incyte Corporation stock logo
INCY
Incyte
7/30/2025Reiterated Rating$77.82$68.00Neutral
Comerica Incorporated stock logo
CMA
Comerica
7/21/2025Set Price Target$64.59$64.00Neutral
Webster Financial Corporation stock logo
WBS
Webster Financial
7/9/2025Reiterated Rating$59.13$69.00Buy
Pinnacle Financial Partners, Inc. stock logo
PNFP
Pinnacle Financial Partners
7/9/2025Reiterated Rating$118.15$121.00Neutral